Skip to content

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

Order Voraxaze

This is a promotional website intended for licensed healthcare professionals
or prescribed patients in the United Kingdom or Republic of Ireland.
Please select one of the following:

I am a patient

Continue

I am a Healthcare Professional

Outside of the UK

United States (EN) Germany (DE)

I am a Healthcare Professional
In the UK

UK-VRX-2600029 Date of Last Revision: April 2026

Resources

Voraxaze resources for your practice

UK-VRX-2600037 Date of Preparation: April 2026

Delayed MTX Elimination in Practice: Recognise Risk, Act Early, Protect Outcomes

Watch this expert-led webinar to understand why early kidney function monitoring and prompt action are critical in managing HDMTX toxicity. Gain practical guidance to support clinical decision-making and improve patient outcomes.

WATCH NOW

UK-VRX-2500082 Date of Preparation: April 2026

AKI in Cancer Patients Receiving HDMTX: Why Early Recognition Matters – BOPA 2025 Symposium

Watch this recording to hear from a nephrologist, haematologist & pharmacist sharing practical insights on delayed methotrexate elimination, early AKI recognition and protecting renal outcomes in patients receiving HDMTX.

WATCH NOW

UK-VRX-2500020 Date of Last Revision: February 2025

Managing delayed MTX elimination with glucarpidase

Watch Anish Tailor, Lead Haematology Pharmacist from UCLH, discuss his approach to managing delayed MTX elimination with glucarpidase in adult patients with lymphoma.

WATCH NOW

UK-VRX-2500022 Date of Last Revision: February 2025

Prevention, management and induced challenges with HDMTX-induced nephrotoxicity

Watch Raakhee Shah, Lead Haematology Pharmacist from UCLH, present her thoughts on the prevention, management, and challenges with HDMTX-induced nephrotoxicity.

WATCH NOW

UK-VRX-2500021 Date of Last Revision: February 2025

Managing delayed MTX elimination with glucarpidase in paediatric patients

Watch Vanessa McLelland, Lead Paediatric Pharmacist from UHBW, present her approach on managing delayed MTX elimination with glucarpidase in paediatric patients.

WATCH NOW

Royal College of Emergency

Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments1
(Version 6, December 2022)

  • These drugs are held in specialist sites for supply in England.
  • Glucarpidase for methotrexate toxicity is held at Oxford Pharmacy Stores.
Learn More

Clinical Commissioning Policy

Clinical Commissioning Policy: Glucarpidase for the urgent treatment of methotrexate induced renal dysfunction2

  • NHS England will commission Glucarpidase for the urgent treatment of methotrexate-induced renal dysfunction in accordance with the criteria outlined in this document.
Learn More

Journal of Cancer research and clinical oncology

A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment
(Published October 2024)

  • Early recognition of DME is important to promptly implement appropriate treatment including, intensified hydration, high-dose leucovorin and, when appropriate, glucarpidase.
Learn More

UK-VRX-2600035 Date of Last Revision: April 2026